Difference between revisions of "Team:ETH Zurich"

(Factor CSS to separate page.)
(Style landing page with sections.)
Line 7: Line 7:
 
<html>
 
<html>
 
<main role="main">
 
<main role="main">
−
<div class="title" style="margin:auto">  
+
<div id="title">  
 
     <a href="https://2017.igem.org/Team:ETH_Zurich">
 
     <a href="https://2017.igem.org/Team:ETH_Zurich">
 
         <img src="https://static.igem.org/mediawiki/2017/c/c3/T--ETH_Zurich--Banner.png"/>
 
         <img src="https://static.igem.org/mediawiki/2017/c/c3/T--ETH_Zurich--Banner.png"/>
Line 13: Line 13:
 
</div>
 
</div>
  
−
    <a href="#start">
+
<a href="#start">
−
        <img class="scroll-ico" src="https://static.igem.org/mediawiki/2017/1/14/T--ETH_Zurich--Scroll.png">
+
    <img class="scroll-ico" src="https://static.igem.org/mediawiki/2017/1/14/T--ETH_Zurich--Scroll.png">
−
    </a>
+
</a>
  
−
<div class="content">
+
<section id="start" class="step">
−
    <div id="start">
+
    <p>Cancer kills over 8 million people every year. That's the entire population of Switzerland!</p>
−
        <p>Cancer kills over 8 million people every year. That's the entire population of Switzerland!</p>
+
    <p>We need more specific therapies because current approaches result in many side-effects.</p>
−
        <p>We need more specific therapies because current approaches result in many side-effects.</p>
+
    <p>That's why we created CATE: Cancer-Targeting E. coli.</p>
−
        <p>That's why we created CATE: Cancer-Targeting E. coli.</p>
+
    <a href="https://2017.igem.org/Team:ETH_Zurich/Background" class="more">Learn more</a>
−
        <a href="https://2017.igem.org/Team:ETH_Zurich/Background" class="more">Learn more</a>
+
    <img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH">
−
        <img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH">
+
</section>
−
    </div>
+
  
−
    <div id="second">
+
<section id="second" class="step">
−
        <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec">
+
    <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec">
−
        <p>CATE consists of the non-pathogenic bacterium  E. coli Nissle that has the intrinsic ability to home specifically in tumors.<br><br> We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.</p>
+
    <p>CATE consists of the non-pathogenic bacterium  E. coli Nissle that has the intrinsic ability to home specifically in tumors.<br><br> We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.</p>
−
        <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a>
+
    <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a>
−
    </div>
+
</section>
  
−
    <div id="third">
+
<section id="third" class="step">
−
        <p>CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor</p>
+
    <p>CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor</p>
−
        <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" class="AND">
+
    <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" class="AND">
−
        <p class="alignright">The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.</p>
+
    <p class="alignright">The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.</p>
−
        <a href="https://2017.igem.org/Team:ETH_Zurich/#" class="more">Design</a>
+
    <a href="https://2017.igem.org/Team:ETH_Zurich/#" class="more">Design</a>
−
    </div>
+
</section>
−
</div>
+
 
</main>
 
</main>
 
<script>
 
<script>

Revision as of 13:52, 17 October 2017

Cancer kills over 8 million people every year. That's the entire population of Switzerland!

We need more specific therapies because current approaches result in many side-effects.

That's why we created CATE: Cancer-Targeting E. coli.

Learn more

CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.

We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.

Project description

CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor

The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.

Design